Open an account

ABVC Biopharma

ABVC · NASDAQ

$0.93+$0.02 (+2.20%)TodayMarket closed ·
Prev close $0.91

About ABVC

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 19 full-time employees. The company went IPO on 2004-11-09. The firm is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.

Employees
19
Headquarters
Fremont, California
Listed
Nov 9, 2004
Sector
Health Care
Industry
Biotechnology
Website
abvcpharma.com

ABVC key statistics

Market cap
24.83M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
89.55K
Volume
11.82K
Open price
$0.92
High today
$0.9899
Low today
$0.92
52 Week high
$3.07
52 Week low
$0.7069

ABVC Biopharma (ABVC) at a glance

As of Oct 20, 2026, ABVC Biopharma (ABVC) shares are priced at $0.93, giving the company a market cap of 24.83M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.92 and $0.9899. The current price is 1.1% above the day's low and 6.1% below its high.

Volume so far is 11.82K shares, below the average of 89.55K shares a day.

Over the past year ABVC Biopharma has ranged from $0.7069 to $3.07, and now sits 9% of the way up that range.

ABVC Biopharma met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q1 FY25 it reported -$0.06 per share against an estimate of $0.00.

ABVC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 22.9% on average.

  1. Q3 FY21: reported -$0.70 per share against an estimate of -$0.408
  2. Q4 FY21: reported -$3.10 per share against an estimate of -$0.408
  3. Q2 FY22: reported -$0.60 per share against an estimate of -$1.27
  4. Q3 FY22: reported -$1.10 per share against an estimate of -$1.27
  5. Q4 FY22: reported -$1.50 per share against an estimate of -$1.53
  6. Q1 FY23: reported -$0.60 per share against an estimate of -$0.51
  7. Q2 FY23: reported -$0.68 per share against an estimate of -$0.0612
  8. Q1 FY25: reported -$0.06 per share against an estimate of $0.00

ABVC news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseGlobe Newswire

    ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

  • Press releaseGlobe Newswire

    ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

Similar companies

Companies in the same industry as ABVC Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.